Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial
@article{Zhang2020ImmunogenicityAS, title={Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial}, author={Y. Zhang and G. Zeng and H-X Pan and C. Li and B. Kan and Y-L Hu and H. Y. Mao and Q.-Q. Xin and K. Chu and W.-X. Han and Z. Chen and R. Tang and W.-D. Yin and X. Chen and X. Gong and C. Qin and Y.-S. Hu and X-Y Liu and G.-L. Cui and C. Jiang and H-m Zhang and J. Li and M. Yang and X.-J. Lian and Y. Song and J. Lu and X. Wang and M. Xu and Q. Gao and F. Zhu}, journal={medRxiv}, year={2020} }
BACKGROUND The top priority for the control of COVID-19 pandemic currently is the development of a vaccine. A phase 2 trial conducted to further evaluate the immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac). METHODS We conducted a randomized, double-blind, placebo-controlled trial to evaluate the optimal dose, immunogenicity and safety of the CoronaVac. A total of 600 healthy adults aged 18-59 years were randomly assigned to receive 2 injections of the trial vaccine at… CONTINUE READING
Topics from this paper
24 Citations
Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: a phase 1, double-blind, randomised control trial
- Medicine
- medRxiv
- 2020
- PDF
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
- Medicine
- The Lancet Infectious Diseases
- 2021
Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward
- Medicine
- Human vaccines & immunotherapeutics
- 2020
- 1
Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection
- Medicine
- Advanced Drug Delivery Reviews
- 2020
- 2
A systematic review of SARS-CoV-2 vaccine candidates
- Medicine
- Signal Transduction and Targeted Therapy
- 2020
- 24
- PDF
References
SHOWING 1-10 OF 16 REFERENCES
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- Medicine
- The Lancet
- 2020
- 341
- PDF
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
- Medicine
- medRxiv
- 2020
- 59
- PDF
Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial.
- Medicine
- Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
- 2019
- 3
Comparison of Immunogenicity Between Inactivated and Live Attenuated Hepatitis A Vaccines Among Young Adults: A 3-Year Follow-up Study.
- Medicine
- The Journal of infectious diseases
- 2015
- 8
- PDF
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- Medicine
- The New England journal of medicine
- 2020
- 427
- PDF
Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients
- Medicine
- medRxiv
- 2020
- 76
- PDF
Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection
- Medicine
- medRxiv
- 2020
- 223
- PDF
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
- Biology, Medicine
- The Lancet
- 2020
- 4,336
- PDF